Skip to main content
Erschienen in: Hepatology International 2/2010

01.06.2010 | Review Article

Autoimmune hepatitis: new paradigms in the pathogenesis, diagnosis, and management

verfasst von: Ye H. Oo, Stefan G. Hubscher, David H. Adams

Erschienen in: Hepatology International | Ausgabe 2/2010

Einloggen, um Zugang zu erhalten

Abstract

Autoimmune hepatitis (AIH), primary biliary cirrhosis, and primary sclerosing cholangitis are the three major autoimmune diseases affecting the liver, and of these three, AIH is the most typical autoimmune disease being characterized by a T-cell-rich infiltrate, raised circulating γ-globulins, autoantibodies, HLA associations, and links with other autoimmune diseases. It is the only one, of the three diseases, that responds well to immunosuppressive therapy. AIH is caused by dysregulation of immunoregulatory networks and the consequent emergence of autoreactive T cells that orchestrate a progressive destruction of hepatocytes leading untreated to liver failure. T cells play a major role in the immunopathogenesis, and both CD4+ and CD8+ T cells are involved together with effector responses mediated by NK cells, γδ T cells, and macrophages. A number of triggering factors have been proposed including viruses, xenobiotics, and drugs, but none have been conclusively shown to be involved in pathogenesis.
Literatur
1.
Zurück zum Zitat Czaja AJ, Carpenter HA. Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly. Hepatology 2006;43(3):532–538PubMed Czaja AJ, Carpenter HA. Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly. Hepatology 2006;43(3):532–538PubMed
2.
Zurück zum Zitat Miyake Y, Iwasaki Y, Sakaguchi K, Shiratori Y. Clinical features of Japanese male patients with type 1 autoimmune hepatitis. Aliment Pharmacol Ther 2006;24(3):519–523PubMed Miyake Y, Iwasaki Y, Sakaguchi K, Shiratori Y. Clinical features of Japanese male patients with type 1 autoimmune hepatitis. Aliment Pharmacol Ther 2006;24(3):519–523PubMed
3.
Zurück zum Zitat Al Chalabi T, Boccato S, Portmann BC, Mcfarlane IG, Heneghan MA. Autoimmune hepatitis (AIH) in the elderly: a systematic retrospective analysis of a large group of consecutive patients with definite AIH followed at a tertiary referral centre. J Hepatol 2006;45(4):575–583PubMed Al Chalabi T, Boccato S, Portmann BC, Mcfarlane IG, Heneghan MA. Autoimmune hepatitis (AIH) in the elderly: a systematic retrospective analysis of a large group of consecutive patients with definite AIH followed at a tertiary referral centre. J Hepatol 2006;45(4):575–583PubMed
4.
Zurück zum Zitat Miyake Y, Iwasaki Y, Terada R, Onishi T, Okamoto R, Sakai N, et al. Clinical characteristics of fulminant-type autoimmune hepatitis: an analysis of eleven cases. Aliment Pharmacol Ther 2006;23(9):1347–1353PubMed Miyake Y, Iwasaki Y, Terada R, Onishi T, Okamoto R, Sakai N, et al. Clinical characteristics of fulminant-type autoimmune hepatitis: an analysis of eleven cases. Aliment Pharmacol Ther 2006;23(9):1347–1353PubMed
5.
Zurück zum Zitat Nikias GA, Batts KP, Czaja AJ. The nature and prognostic implications of autoimmune hepatitis with an acute presentation. J Hepatol 1994;21(5):866–871PubMed Nikias GA, Batts KP, Czaja AJ. The nature and prognostic implications of autoimmune hepatitis with an acute presentation. J Hepatol 1994;21(5):866–871PubMed
6.
Zurück zum Zitat Burgart LJ, Batts KP, Ludwig J, Nikias GA, Czaja AJ. Recent onset autoimmune hepatitis. Biopsy findings and clinical correlations. Am J Surg Pathol 1995;19(6):699–708PubMed Burgart LJ, Batts KP, Ludwig J, Nikias GA, Czaja AJ. Recent onset autoimmune hepatitis. Biopsy findings and clinical correlations. Am J Surg Pathol 1995;19(6):699–708PubMed
7.
Zurück zum Zitat Terrabuio DR, Abrantes-Lemos CP, Carrilho FJ, Cancado EL. Follow-up of pregnant women with autoimmune hepatitis: the disease behavior along with maternal and fetal outcomes. J Clin Gastroenterol 2009;43(4):350–356PubMed Terrabuio DR, Abrantes-Lemos CP, Carrilho FJ, Cancado EL. Follow-up of pregnant women with autoimmune hepatitis: the disease behavior along with maternal and fetal outcomes. J Clin Gastroenterol 2009;43(4):350–356PubMed
8.
Zurück zum Zitat Werner M, Bjornsson E, Prytz H, Lindgren S, Almer S, Broome U, et al. Autoimmune hepatitis among fertile women: strategies during pregnancy and breastfeeding? Scand J Gastroenterol 2007;42(8):986–991PubMed Werner M, Bjornsson E, Prytz H, Lindgren S, Almer S, Broome U, et al. Autoimmune hepatitis among fertile women: strategies during pregnancy and breastfeeding? Scand J Gastroenterol 2007;42(8):986–991PubMed
9.
Zurück zum Zitat Schramm C, Herkel J, Beuers U, Kanzler S, Galle PR, Lohse AW. Pregnancy in autoimmune hepatitis: outcome and risk factors. Am J Gastroenterol 2006;101(3):556–560PubMed Schramm C, Herkel J, Beuers U, Kanzler S, Galle PR, Lohse AW. Pregnancy in autoimmune hepatitis: outcome and risk factors. Am J Gastroenterol 2006;101(3):556–560PubMed
10.
Zurück zum Zitat Heneghan MA, Norris SM, O’Grady JG, Harrison PM, Mcfarlane IG. Management and outcome of pregnancy in autoimmune hepatitis. Gut 2001;48(1):97–102PubMed Heneghan MA, Norris SM, O’Grady JG, Harrison PM, Mcfarlane IG. Management and outcome of pregnancy in autoimmune hepatitis. Gut 2001;48(1):97–102PubMed
11.
Zurück zum Zitat Aluvihare VR, Kallikourdis M, Betz AG. Regulatory T cells mediate maternal tolerance to the fetus. Nat Immunol 2004;5(3):266–271PubMed Aluvihare VR, Kallikourdis M, Betz AG. Regulatory T cells mediate maternal tolerance to the fetus. Nat Immunol 2004;5(3):266–271PubMed
12.
Zurück zum Zitat Fusconi M, Vannini A, Dall’Aglio AC, Pappas G, Cassani F, Ballardini G, et al. Anti-cyclic citrullinated peptide antibodies in type 1 autoimmune hepatitis. Aliment Pharmacol Ther 2005;22(10):951–955PubMed Fusconi M, Vannini A, Dall’Aglio AC, Pappas G, Cassani F, Ballardini G, et al. Anti-cyclic citrullinated peptide antibodies in type 1 autoimmune hepatitis. Aliment Pharmacol Ther 2005;22(10):951–955PubMed
13.
Zurück zum Zitat Montano-Loza A, Czaja AJ, Carpenter HA, Piette A, Murphy D, Shums Z, et al. Frequency and significance of antibodies to cyclic citrullinated peptide in type 1 autoimmune hepatitis. Autoimmunity 2006;39(4):341–348PubMed Montano-Loza A, Czaja AJ, Carpenter HA, Piette A, Murphy D, Shums Z, et al. Frequency and significance of antibodies to cyclic citrullinated peptide in type 1 autoimmune hepatitis. Autoimmunity 2006;39(4):341–348PubMed
14.
Zurück zum Zitat Ben-Ari Z, Broida E, Monselise Y, Kazatsker A, Baruch J, Pappo O, et al. Syncytial giant-cell hepatitis due to autoimmune hepatitis type II (LKM1+) presenting as subfulminant hepatitis. Am J Gastroenterol 2000;95(3):799–801PubMed Ben-Ari Z, Broida E, Monselise Y, Kazatsker A, Baruch J, Pappo O, et al. Syncytial giant-cell hepatitis due to autoimmune hepatitis type II (LKM1+) presenting as subfulminant hepatitis. Am J Gastroenterol 2000;95(3):799–801PubMed
15.
Zurück zum Zitat Devaney K, Goodman ZD, Ishak KG. Postinfantile giant-cell transformation in hepatitis. Hepatology 1992;16(2):327–333PubMed Devaney K, Goodman ZD, Ishak KG. Postinfantile giant-cell transformation in hepatitis. Hepatology 1992;16(2):327–333PubMed
16.
Zurück zum Zitat Carpenter HA, Czaja AJ. The role of histologic evaluation in the diagnosis and management of autoimmune hepatitis and its variants. Clin Liver Dis 2002;6(3):685–705PubMed Carpenter HA, Czaja AJ. The role of histologic evaluation in the diagnosis and management of autoimmune hepatitis and its variants. Clin Liver Dis 2002;6(3):685–705PubMed
17.
Zurück zum Zitat Burt AD, Portmann BC, Ferrell LD, MacSween R. Autoimmune hepatitis. In Pathology of the Liver. Edinburgh: Churchill Livingstone; 2007. 493–517 Burt AD, Portmann BC, Ferrell LD, MacSween R. Autoimmune hepatitis. In Pathology of the Liver. Edinburgh: Churchill Livingstone; 2007. 493–517
18.
Zurück zum Zitat Feld JJ. Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome. Hepatology 2005;42(1):53–62PubMed Feld JJ. Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome. Hepatology 2005;42(1):53–62PubMed
19.
Zurück zum Zitat Cotler SJ, Jakate S, Jensen DM. Resolution of cirrhosis in autoimmune hepatitis with corticosteroid therapy. J Clin Gastroenterol 2001;32(5):428–430PubMed Cotler SJ, Jakate S, Jensen DM. Resolution of cirrhosis in autoimmune hepatitis with corticosteroid therapy. J Clin Gastroenterol 2001;32(5):428–430PubMed
20.
Zurück zum Zitat Czaja AJ, Carpenter HA. Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis. J Hepatol 2004;40(4):646–652PubMed Czaja AJ, Carpenter HA. Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis. J Hepatol 2004;40(4):646–652PubMed
21.
Zurück zum Zitat Czaja AJ, Carpenter HA. Progressive fibrosis during corticosteroid therapy of autoimmune hepatitis. Hepatology 2004;39(6):1631–1638PubMed Czaja AJ, Carpenter HA. Progressive fibrosis during corticosteroid therapy of autoimmune hepatitis. Hepatology 2004;39(6):1631–1638PubMed
22.
Zurück zum Zitat Johnson PJ, Mcfarlane IG. Meeting report: International Autoimmune Hepatitis Group. Hepatology 1993;18(4):998–1005PubMed Johnson PJ, Mcfarlane IG. Meeting report: International Autoimmune Hepatitis Group. Hepatology 1993;18(4):998–1005PubMed
23.
Zurück zum Zitat Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999;31(5):929–938PubMed Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999;31(5):929–938PubMed
24.
Zurück zum Zitat Hennes EM, Zeniya M, Czaja AJ, Pares A, Dalekos GN, Krawitt EL, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008;48(1):169–176PubMed Hennes EM, Zeniya M, Czaja AJ, Pares A, Dalekos GN, Krawitt EL, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008;48(1):169–176PubMed
25.
Zurück zum Zitat Czaja AJ. Performance parameters of the diagnostic scoring systems for autoimmune hepatitis. Hepatology 2008;48(5):1540–1548PubMed Czaja AJ. Performance parameters of the diagnostic scoring systems for autoimmune hepatitis. Hepatology 2008;48(5):1540–1548PubMed
26.
Zurück zum Zitat Yeoman AD, Westbrook RH, Al-Chalabi T, Carey I, Heaton ND, Portmann BC, et al. Diagnostic value and utility of the simplified International Autoimmune Hepatitis Group (IAIHG) criteria in acute and chronic liver disease. Hepatology 2009;50(2):538–545PubMed Yeoman AD, Westbrook RH, Al-Chalabi T, Carey I, Heaton ND, Portmann BC, et al. Diagnostic value and utility of the simplified International Autoimmune Hepatitis Group (IAIHG) criteria in acute and chronic liver disease. Hepatology 2009;50(2):538–545PubMed
27.
Zurück zum Zitat Wiegard C, Schramm C, Lohse AW. Scoring systems for the diagnosis of autoimmune hepatitis: past, present, and future. Semin Liver Dis 2009;29(3):254–261PubMed Wiegard C, Schramm C, Lohse AW. Scoring systems for the diagnosis of autoimmune hepatitis: past, present, and future. Semin Liver Dis 2009;29(3):254–261PubMed
28.
Zurück zum Zitat Roozendaal C, de Jong MA, van den Berg AP, van Wijk RT, Limburg PC, Kallenberg CG. Clinical significance of anti-neutrophil cytoplasmic antibodies (ANCA) in autoimmune liver diseases. J Hepatol 2000;32(5):734–741PubMed Roozendaal C, de Jong MA, van den Berg AP, van Wijk RT, Limburg PC, Kallenberg CG. Clinical significance of anti-neutrophil cytoplasmic antibodies (ANCA) in autoimmune liver diseases. J Hepatol 2000;32(5):734–741PubMed
29.
Zurück zum Zitat Roozendaal C, Kallenberg CG. Anti-neutrophil cytoplasm autoantibodies (ANCA) in autoimmune liver diseases. Hepatogastroenterology 1999;46(30):3034–3040PubMed Roozendaal C, Kallenberg CG. Anti-neutrophil cytoplasm autoantibodies (ANCA) in autoimmune liver diseases. Hepatogastroenterology 1999;46(30):3034–3040PubMed
30.
Zurück zum Zitat Duchini A, McHutchison JG, Pockros PJ. LKM-positive autoimmune hepatitis in the western United States: a case series. Am J Gastroenterol 2000;95(11):3238–3241PubMed Duchini A, McHutchison JG, Pockros PJ. LKM-positive autoimmune hepatitis in the western United States: a case series. Am J Gastroenterol 2000;95(11):3238–3241PubMed
31.
Zurück zum Zitat Bridoux-Henno L, Maggiore G, Johanet C, Fabre M, Vajro P, Dommergues JP, et al. Features and outcome of autoimmune hepatitis type 2 presenting with isolated positivity for anti-liver cytosol antibody. Clin Gastroenterol Hepatol 2004;2(9):825–830PubMed Bridoux-Henno L, Maggiore G, Johanet C, Fabre M, Vajro P, Dommergues JP, et al. Features and outcome of autoimmune hepatitis type 2 presenting with isolated positivity for anti-liver cytosol antibody. Clin Gastroenterol Hepatol 2004;2(9):825–830PubMed
32.
Zurück zum Zitat Wies I, Brunner S, Henninger J, Herkel J, Kanzler S, Meyer zum Buschenfelde KH, et al. Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis. Lancet 2000;355(9214):1510–1515PubMed Wies I, Brunner S, Henninger J, Herkel J, Kanzler S, Meyer zum Buschenfelde KH, et al. Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis. Lancet 2000;355(9214):1510–1515PubMed
33.
Zurück zum Zitat Kanzler S, Weidemann C, Gerken G, Lohr HF, Galle PR, Meyer zum Buschenfelde KH, et al. Clinical significance of autoantibodies to soluble liver antigen in autoimmune hepatitis. J Hepatol 1999;31(4):635–640PubMed Kanzler S, Weidemann C, Gerken G, Lohr HF, Galle PR, Meyer zum Buschenfelde KH, et al. Clinical significance of autoantibodies to soluble liver antigen in autoimmune hepatitis. J Hepatol 1999;31(4):635–640PubMed
34.
Zurück zum Zitat Kirk AP, Jain S, Pocock S, Thomas HC, Sherlock S. Late results of the Royal Free Hospital prospective controlled trial of prednisolone therapy in hepatitis B surface antigen negative chronic active hepatitis. Gut 1980;21(1):78–83PubMed Kirk AP, Jain S, Pocock S, Thomas HC, Sherlock S. Late results of the Royal Free Hospital prospective controlled trial of prednisolone therapy in hepatitis B surface antigen negative chronic active hepatitis. Gut 1980;21(1):78–83PubMed
35.
Zurück zum Zitat Murray-Lyon IM, Stern RB, Williams R. Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet 1973;1(7806):735–737PubMed Murray-Lyon IM, Stern RB, Williams R. Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet 1973;1(7806):735–737PubMed
36.
Zurück zum Zitat Kogan J, Safadi R, Ashur Y, Shouval D, Ilan Y. Prognosis of symptomatic versus asymptomatic autoimmune hepatitis: a study of 68 patients. J Clin Gastroenterol 2002;35(1):75–81PubMed Kogan J, Safadi R, Ashur Y, Shouval D, Ilan Y. Prognosis of symptomatic versus asymptomatic autoimmune hepatitis: a study of 68 patients. J Clin Gastroenterol 2002;35(1):75–81PubMed
37.
Zurück zum Zitat Verma S, Gunuwan B, Mendler M, Govindrajan S, Redeker A. Factors predicting relapse and poor outcome in type I autoimmune hepatitis: role of cirrhosis development, patterns of transaminases during remission and plasma cell activity in the liver biopsy. Am J Gastroenterol 2004;99(8):1510–1516PubMed Verma S, Gunuwan B, Mendler M, Govindrajan S, Redeker A. Factors predicting relapse and poor outcome in type I autoimmune hepatitis: role of cirrhosis development, patterns of transaminases during remission and plasma cell activity in the liver biopsy. Am J Gastroenterol 2004;99(8):1510–1516PubMed
38.
Zurück zum Zitat Yeoman AD, Al-Chalabi T, Karani JB, Quaglia A, Devlin J, Mieli-Vergani G, et al. Evaluation of risk factors in the development of hepatocellular carcinoma in autoimmune hepatitis: implications for follow-up and screening. Hepatology 2008;48(3):863–870PubMed Yeoman AD, Al-Chalabi T, Karani JB, Quaglia A, Devlin J, Mieli-Vergani G, et al. Evaluation of risk factors in the development of hepatocellular carcinoma in autoimmune hepatitis: implications for follow-up and screening. Hepatology 2008;48(3):863–870PubMed
39.
Zurück zum Zitat Lohse AW, zum Buschenfelde KH, Franz B, Kanzler S, Gerken G, Dienes HP. Characterization of the overlap syndrome of primary biliary cirrhosis (PBC) and autoimmune hepatitis: evidence for it being a hepatitic form of PBC in genetically susceptible individuals. Hepatology 1999;29(4):1078–1084PubMed Lohse AW, zum Buschenfelde KH, Franz B, Kanzler S, Gerken G, Dienes HP. Characterization of the overlap syndrome of primary biliary cirrhosis (PBC) and autoimmune hepatitis: evidence for it being a hepatitic form of PBC in genetically susceptible individuals. Hepatology 1999;29(4):1078–1084PubMed
40.
Zurück zum Zitat Kaya M, Angulo P, Lindor KD. Overlap of autoimmune hepatitis and primary sclerosing cholangitis: an evaluation of a modified scoring system. J Hepatol 2000;33(4):537–542PubMed Kaya M, Angulo P, Lindor KD. Overlap of autoimmune hepatitis and primary sclerosing cholangitis: an evaluation of a modified scoring system. J Hepatol 2000;33(4):537–542PubMed
41.
Zurück zum Zitat Talwalkar JA, Keach JC, Angulo P, Lindor KD. Overlap of autoimmune hepatitis and primary biliary cirrhosis: an evaluation of a modified scoring system. Am J Gastroenterol 2002;97(5):1191–1197PubMed Talwalkar JA, Keach JC, Angulo P, Lindor KD. Overlap of autoimmune hepatitis and primary biliary cirrhosis: an evaluation of a modified scoring system. Am J Gastroenterol 2002;97(5):1191–1197PubMed
42.
Zurück zum Zitat Beuers U, Rust C. Overlap syndromes. Semin Liver Dis 2005;25(3):311–320PubMed Beuers U, Rust C. Overlap syndromes. Semin Liver Dis 2005;25(3):311–320PubMed
43.
Zurück zum Zitat Abdo AA, Bain VG, Kichian K, Lee SS. Evolution of autoimmune hepatitis to primary sclerosing cholangitis: a sequential syndrome. Hepatology 2002;36(6):1393–1399PubMed Abdo AA, Bain VG, Kichian K, Lee SS. Evolution of autoimmune hepatitis to primary sclerosing cholangitis: a sequential syndrome. Hepatology 2002;36(6):1393–1399PubMed
44.
Zurück zum Zitat Adams DH, Eksteen B. Aberrant homing of mucosal T cells and extra-intestinal manifestations of inflammatory bowel disease. Nat Rev Immunol 2006;6(3):244–251PubMed Adams DH, Eksteen B. Aberrant homing of mucosal T cells and extra-intestinal manifestations of inflammatory bowel disease. Nat Rev Immunol 2006;6(3):244–251PubMed
45.
Zurück zum Zitat Bertolino P, Klimpel G, Lemon SM. Hepatic inflammation and immunity: a summary of a conference on the function of the immune system within the liver. Hepatology 2000;31(6):1374–1378PubMed Bertolino P, Klimpel G, Lemon SM. Hepatic inflammation and immunity: a summary of a conference on the function of the immune system within the liver. Hepatology 2000;31(6):1374–1378PubMed
46.
Zurück zum Zitat Chazouilleres O, Wendum D, Serfaty L, Rosmorduc O, Poupon R. Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. J Hepatol 2006;44(2):400–406PubMed Chazouilleres O, Wendum D, Serfaty L, Rosmorduc O, Poupon R. Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. J Hepatol 2006;44(2):400–406PubMed
47.
Zurück zum Zitat Poupon R, Chazouilleres O, Corpechot C, Chretien Y. Development of autoimmune hepatitis in patients with typical primary biliary cirrhosis. Hepatology 2006;44(1):85–90PubMed Poupon R, Chazouilleres O, Corpechot C, Chretien Y. Development of autoimmune hepatitis in patients with typical primary biliary cirrhosis. Hepatology 2006;44(1):85–90PubMed
48.
Zurück zum Zitat Saich R, Chapman R. Primary sclerosing cholangitis, autoimmune hepatitis and overlap syndromes in inflammatory bowel disease. World J Gastroenterol 2008;14(3):331–337PubMed Saich R, Chapman R. Primary sclerosing cholangitis, autoimmune hepatitis and overlap syndromes in inflammatory bowel disease. World J Gastroenterol 2008;14(3):331–337PubMed
49.
Zurück zum Zitat Perdigoto R, Carpenter HA, Czaja AJ. Frequency and significance of chronic ulcerative colitis in severe corticosteroid-treated autoimmune hepatitis. J Hepatol 1992;14(2–3):325–331PubMed Perdigoto R, Carpenter HA, Czaja AJ. Frequency and significance of chronic ulcerative colitis in severe corticosteroid-treated autoimmune hepatitis. J Hepatol 1992;14(2–3):325–331PubMed
50.
Zurück zum Zitat McNair AN, Moloney M, Portmann BC, Williams R, Mcfarlane IG. Autoimmune hepatitis overlapping with primary sclerosing cholangitis in five cases. Am J Gastroenterol 1998;93(5):777–784PubMed McNair AN, Moloney M, Portmann BC, Williams R, Mcfarlane IG. Autoimmune hepatitis overlapping with primary sclerosing cholangitis in five cases. Am J Gastroenterol 1998;93(5):777–784PubMed
51.
Zurück zum Zitat van Buuren HR, van Hoogstraten HJE, Terkivatan T, Schalm SW, Vleggaar FP. High prevalence of autoimmune hepatitis among patients with primary sclerosing cholangitis. J Hepatol 2000;33(4):543–548PubMed van Buuren HR, van Hoogstraten HJE, Terkivatan T, Schalm SW, Vleggaar FP. High prevalence of autoimmune hepatitis among patients with primary sclerosing cholangitis. J Hepatol 2000;33(4):543–548PubMed
52.
Zurück zum Zitat Grant AJ, Lalor PF, Salmi M, Jalkanen S, Adams DH. Homing of mucosal lymphocytes to the liver in the pathogenesis of hepatic complications of inflammatory bowel disease. Lancet 2002;359(9301):150–157PubMed Grant AJ, Lalor PF, Salmi M, Jalkanen S, Adams DH. Homing of mucosal lymphocytes to the liver in the pathogenesis of hepatic complications of inflammatory bowel disease. Lancet 2002;359(9301):150–157PubMed
53.
Zurück zum Zitat Agace WW. T-cell recruitment to the intestinal mucosa. Trends Immunol 2008;29(11):514–522PubMed Agace WW. T-cell recruitment to the intestinal mucosa. Trends Immunol 2008;29(11):514–522PubMed
54.
Zurück zum Zitat Eksteen B, Grant AJ, Miles A, Curbishley SM, Lalor PF, Hubscher SG, et al. Hepatic endothelial CCL25 mediates the recruitment of CCR9+ gut-homing lymphocytes to the liver in primary sclerosing cholangitis. J Exp Med 2004;200(11):1511–1517PubMed Eksteen B, Grant AJ, Miles A, Curbishley SM, Lalor PF, Hubscher SG, et al. Hepatic endothelial CCL25 mediates the recruitment of CCR9+ gut-homing lymphocytes to the liver in primary sclerosing cholangitis. J Exp Med 2004;200(11):1511–1517PubMed
55.
Zurück zum Zitat Gregorio GV, Portmann B, Karani J, Harrison P, Donaldson PT, Vergani D, et al. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology 2001;33(3):544–553PubMed Gregorio GV, Portmann B, Karani J, Harrison P, Donaldson PT, Vergani D, et al. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology 2001;33(3):544–553PubMed
56.
Zurück zum Zitat Czaja AJ, Carpenter HA. Autoimmune hepatitis with incidental histologic features of bile duct injury. Hepatology 2001;34(4 Pt 1):659–865PubMed Czaja AJ, Carpenter HA. Autoimmune hepatitis with incidental histologic features of bile duct injury. Hepatology 2001;34(4 Pt 1):659–865PubMed
57.
Zurück zum Zitat Abdalian R, Dhar P, Jhaveri K, Haider M, Guindi M, Heathcote EJ. Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis: evaluating the role of routine magnetic resonance imaging. Hepatology 2008;47(3):949–957PubMed Abdalian R, Dhar P, Jhaveri K, Haider M, Guindi M, Heathcote EJ. Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis: evaluating the role of routine magnetic resonance imaging. Hepatology 2008;47(3):949–957PubMed
58.
Zurück zum Zitat O’Brien C, Joshi S, Feld JJ, Guindi M, Dienes HP, Heathcote EJ. Long-term follow-up of antimitochondrial antibody-positive autoimmune hepatitis. Hepatology 2008;48(2):550–556PubMed O’Brien C, Joshi S, Feld JJ, Guindi M, Dienes HP, Heathcote EJ. Long-term follow-up of antimitochondrial antibody-positive autoimmune hepatitis. Hepatology 2008;48(2):550–556PubMed
59.
Zurück zum Zitat Donaldson PT, Czaja AJ. Genetic effects on susceptibility, clinical expression, and treatment outcome of type 1 autoimmune hepatitis. Clin Liver Dis 2002;6(3):707–725PubMed Donaldson PT, Czaja AJ. Genetic effects on susceptibility, clinical expression, and treatment outcome of type 1 autoimmune hepatitis. Clin Liver Dis 2002;6(3):707–725PubMed
60.
Zurück zum Zitat Czaja AJ. Genetic factors affecting the occurrence, clinical phenotype, and outcome of autoimmune hepatitis. Clin Gastroenterol Hepatol 2008;6(4):379–388PubMed Czaja AJ. Genetic factors affecting the occurrence, clinical phenotype, and outcome of autoimmune hepatitis. Clin Gastroenterol Hepatol 2008;6(4):379–388PubMed
61.
Zurück zum Zitat Pando M, Larriba J, Fernandez GC, Fainboim H, Ciocca M, Ramonet M, et al. Pediatric and adult forms of type I autoimmune hepatitis in Argentina: evidence for differential genetic predisposition. Hepatology 1999;30(6):1374–1380PubMed Pando M, Larriba J, Fernandez GC, Fainboim H, Ciocca M, Ramonet M, et al. Pediatric and adult forms of type I autoimmune hepatitis in Argentina: evidence for differential genetic predisposition. Hepatology 1999;30(6):1374–1380PubMed
62.
Zurück zum Zitat Anderson G, Jenkinson WE, Jones T, Parnell SM, Kinsella FA, White AJ, et al. Establishment and functioning of intrathymic microenvironments. Immunol Rev 2006;209:10–27PubMed Anderson G, Jenkinson WE, Jones T, Parnell SM, Kinsella FA, White AJ, et al. Establishment and functioning of intrathymic microenvironments. Immunol Rev 2006;209:10–27PubMed
63.
Zurück zum Zitat Su MA, Anderson MS. Aire: an update. Curr Opin Immunol 2004;16(6):746–752PubMed Su MA, Anderson MS. Aire: an update. Curr Opin Immunol 2004;16(6):746–752PubMed
64.
Zurück zum Zitat Su MA, Giang K, Zumer K, Jiang H, Oven I, Rinn JL, et al. Mechanisms of an autoimmunity syndrome in mice caused by a dominant mutation in Aire. J Clin Invest 2008;118(5):1712–1726PubMed Su MA, Giang K, Zumer K, Jiang H, Oven I, Rinn JL, et al. Mechanisms of an autoimmunity syndrome in mice caused by a dominant mutation in Aire. J Clin Invest 2008;118(5):1712–1726PubMed
65.
Zurück zum Zitat Djilali-Saiah I, Renous R, Caillat-Zucman S, Debray D, Alvarez F. Linkage disequilibrium between HLA class II region and autoimmune hepatitis in pediatric patients. J Hepatol 2004;40(6):904–909PubMed Djilali-Saiah I, Renous R, Caillat-Zucman S, Debray D, Alvarez F. Linkage disequilibrium between HLA class II region and autoimmune hepatitis in pediatric patients. J Hepatol 2004;40(6):904–909PubMed
66.
Zurück zum Zitat Vogel A, Liermann H, Harms A, Strassburg CP, Manns MP, Obermayer-Straub P. Autoimmune regulator AIRE: evidence for genetic differences between autoimmune hepatitis and hepatitis as part of the autoimmune polyglandular syndrome type 1. Hepatology 2001;33(5):1047–1052PubMed Vogel A, Liermann H, Harms A, Strassburg CP, Manns MP, Obermayer-Straub P. Autoimmune regulator AIRE: evidence for genetic differences between autoimmune hepatitis and hepatitis as part of the autoimmune polyglandular syndrome type 1. Hepatology 2001;33(5):1047–1052PubMed
67.
Zurück zum Zitat Czaja AJ, Santrach PJ, Breanndan MS. Shared genetic risk factors in autoimmune liver disease. Dig Dis Sci 2001;46(1):140–147PubMed Czaja AJ, Santrach PJ, Breanndan MS. Shared genetic risk factors in autoimmune liver disease. Dig Dis Sci 2001;46(1):140–147PubMed
68.
Zurück zum Zitat Mieli-Vergani G, Vergani D. Immunological liver diseases in children. Semin Liver Dis 1998;18(3):271–279PubMed Mieli-Vergani G, Vergani D. Immunological liver diseases in children. Semin Liver Dis 1998;18(3):271–279PubMed
69.
Zurück zum Zitat Lohse AW, Lohr H, Bilo K, Zumbuschenfelde KHM. Recognition and regulation of LKM-specific T-cell clones in LKM-positive autoimmune hepatitis. Hepatology 1994;20:A144. Lohse AW, Lohr H, Bilo K, Zumbuschenfelde KHM. Recognition and regulation of LKM-specific T-cell clones in LKM-positive autoimmune hepatitis. Hepatology 1994;20:A144.
70.
Zurück zum Zitat Donaldson PT. Genetics in autoimmune hepatitis. Semin Liver Dis 2002;22(4):353–364PubMed Donaldson PT. Genetics in autoimmune hepatitis. Semin Liver Dis 2002;22(4):353–364PubMed
71.
Zurück zum Zitat Vergani D, Mieli-Vergani G. Autoimmune hepatitis. Autoimmun Rev 2003;2(5):241–247PubMed Vergani D, Mieli-Vergani G. Autoimmune hepatitis. Autoimmun Rev 2003;2(5):241–247PubMed
72.
Zurück zum Zitat Strassburg CP, Obermayer-Straub P, Manns MP. Autoimmunity in liver diseases. Clin Rev Allergy Immunol 2000;18(2):127–139PubMed Strassburg CP, Obermayer-Straub P, Manns MP. Autoimmunity in liver diseases. Clin Rev Allergy Immunol 2000;18(2):127–139PubMed
73.
Zurück zum Zitat Krawitt EL. Autoimmune hepatitis. N Engl J Med 2006;354(1):54–66PubMed Krawitt EL. Autoimmune hepatitis. N Engl J Med 2006;354(1):54–66PubMed
74.
Zurück zum Zitat Holdener M, Hintermann E, Bayer M, Rhode A, Rodrigo E, Hintereder G, et al. Breaking tolerance to the natural human liver autoantigen cytochrome P450 2D6 by virus infection. J Exp Med 2008;205(6):1409–1422PubMed Holdener M, Hintermann E, Bayer M, Rhode A, Rodrigo E, Hintereder G, et al. Breaking tolerance to the natural human liver autoantigen cytochrome P450 2D6 by virus infection. J Exp Med 2008;205(6):1409–1422PubMed
75.
Zurück zum Zitat Horwitz MS, Sarvetnick N. Viruses, host responses, and autoimmunity. Immunol Rev 1999;169:241–253PubMed Horwitz MS, Sarvetnick N. Viruses, host responses, and autoimmunity. Immunol Rev 1999;169:241–253PubMed
76.
Zurück zum Zitat Costa-Rodriguez EV, Rivino L, Geginat J, Jarrossay D, Gattorno M, Lanzavecchia A, et al. Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat Immunol 2007;8(6):639–646 Costa-Rodriguez EV, Rivino L, Geginat J, Jarrossay D, Gattorno M, Lanzavecchia A, et al. Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat Immunol 2007;8(6):639–646
77.
Zurück zum Zitat Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 2006;24(2):179–189PubMed Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 2006;24(2):179–189PubMed
78.
Zurück zum Zitat Wilson NJ, Boniface K, Chan JR, McKenzie BS, Blumenschein WM, Mattson JD, et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 2007;8(9):950–957PubMed Wilson NJ, Boniface K, Chan JR, McKenzie BS, Blumenschein WM, Mattson JD, et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 2007;8(9):950–957PubMed
79.
Zurück zum Zitat Costa-Rodriguez EV, Napolitani G, Lanzavecchia A, Sallusto F. Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol 2007;8(9):942–949 Costa-Rodriguez EV, Napolitani G, Lanzavecchia A, Sallusto F. Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol 2007;8(9):942–949
80.
Zurück zum Zitat Gerosa F, Baldani-Guerra B, Lyakh LA, Batoni G, Esin S, Winkler-Pickett RT, et al. Differential regulation of interleukin 12 and interleukin 23 production in human dendritic cells. J Exp Med 2008;205(6):1447–1461PubMed Gerosa F, Baldani-Guerra B, Lyakh LA, Batoni G, Esin S, Winkler-Pickett RT, et al. Differential regulation of interleukin 12 and interleukin 23 production in human dendritic cells. J Exp Med 2008;205(6):1447–1461PubMed
81.
Zurück zum Zitat Ivanov II, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, Lafaille JJ, et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 2006;126(6):1121–1133PubMed Ivanov II, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, Lafaille JJ, et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 2006;126(6):1121–1133PubMed
82.
Zurück zum Zitat Yang XO, Pappu BP, Nurieva R, Akimzhanov A, Kang HS, Chung Y, et al. T helper 17 lineage differentiation is programmed by orphan nuclear receptors ROR alpha and ROR gamma. Immunity 2008;28(1):29–39PubMed Yang XO, Pappu BP, Nurieva R, Akimzhanov A, Kang HS, Chung Y, et al. T helper 17 lineage differentiation is programmed by orphan nuclear receptors ROR alpha and ROR gamma. Immunity 2008;28(1):29–39PubMed
83.
Zurück zum Zitat Kimura A, Naka T, Nohara K, Fujii-Kuriyama Y, Kishimoto T. Aryl hydrocarbon receptor regulates Stat1 activation and participates in the development of Th17 cells. Proc Natl Acad Sci USA 2008;105(28):9721–9726PubMed Kimura A, Naka T, Nohara K, Fujii-Kuriyama Y, Kishimoto T. Aryl hydrocarbon receptor regulates Stat1 activation and participates in the development of Th17 cells. Proc Natl Acad Sci USA 2008;105(28):9721–9726PubMed
84.
Zurück zum Zitat Veldhoen M, Hirota K, Christensen J, O’Garra A, Stockinger B. Natural agonists for aryl hydrocarbon receptor in culture medium are essential for optimal differentiation of Th17 T cells. J Exp Med 2009;206(1):43–49PubMed Veldhoen M, Hirota K, Christensen J, O’Garra A, Stockinger B. Natural agonists for aryl hydrocarbon receptor in culture medium are essential for optimal differentiation of Th17 T cells. J Exp Med 2009;206(1):43–49PubMed
85.
Zurück zum Zitat Nguyen LP, Bradfield CA. The search for endogenous activators of the aryl hydrocarbon receptor. Chem Res Toxicol 2008;21(1):102–116PubMed Nguyen LP, Bradfield CA. The search for endogenous activators of the aryl hydrocarbon receptor. Chem Res Toxicol 2008;21(1):102–116PubMed
86.
Zurück zum Zitat Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005;201(2):233–240PubMed Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005;201(2):233–240PubMed
87.
Zurück zum Zitat Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly MJ, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006;314(5804):1461–1463PubMed Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly MJ, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006;314(5804):1461–1463PubMed
88.
Zurück zum Zitat Kotake S, Udagawa N, Takahashi N, Matsuzaki K, Itoh K, Ishiyama S, et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 1999;103(9):1345–1352PubMed Kotake S, Udagawa N, Takahashi N, Matsuzaki K, Itoh K, Ishiyama S, et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 1999;103(9):1345–1352PubMed
89.
Zurück zum Zitat Lock C, Hermans G, Pedotti R, Brendolan A, Schadt E, Garren H, et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med 2002;8(5):500–558PubMed Lock C, Hermans G, Pedotti R, Brendolan A, Schadt E, Garren H, et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med 2002;8(5):500–558PubMed
90.
Zurück zum Zitat Pene J, Chevalier S, Preisser L, Venereau E, Guilleux MH, Ghannam S, et al. Chronically inflamed human tissues are infiltrated by highly differentiated Th17 lymphocytes. J Immunol 2008;180(11):7423–7430PubMed Pene J, Chevalier S, Preisser L, Venereau E, Guilleux MH, Ghannam S, et al. Chronically inflamed human tissues are infiltrated by highly differentiated Th17 lymphocytes. J Immunol 2008;180(11):7423–7430PubMed
91.
Zurück zum Zitat Harada K, Shimoda S, Sato Y, Isse K, Ikeda H, Nakanuma Y. Periductal interleukin-17 production in association with biliary innate immunity contributes to the pathogenesis of cholangiopathy in primary biliary cirrhosis. Clin Exp Immunol 2009;157(2):261–270PubMed Harada K, Shimoda S, Sato Y, Isse K, Ikeda H, Nakanuma Y. Periductal interleukin-17 production in association with biliary innate immunity contributes to the pathogenesis of cholangiopathy in primary biliary cirrhosis. Clin Exp Immunol 2009;157(2):261–270PubMed
92.
Zurück zum Zitat Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell 2000;101(5):455–458PubMed Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell 2000;101(5):455–458PubMed
93.
Zurück zum Zitat Sakaguchi S. Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004;22:531–562PubMed Sakaguchi S. Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004;22:531–562PubMed
94.
Zurück zum Zitat Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 2005;6(4):345–352PubMed Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 2005;6(4):345–352PubMed
95.
Zurück zum Zitat Ruprecht CR, Gattorno M, Ferlito F, Gregorio A, Martini A, Lanzavecchia A, et al. Coexpression of CD25 and CD27 identifies FoxP3+ regulatory T cells in inflamed synovia. J Exp Med 2005;201(11):1793–1803PubMed Ruprecht CR, Gattorno M, Ferlito F, Gregorio A, Martini A, Lanzavecchia A, et al. Coexpression of CD25 and CD27 identifies FoxP3+ regulatory T cells in inflamed synovia. J Exp Med 2005;201(11):1793–1803PubMed
96.
Zurück zum Zitat Seddiki N, Santner-Nanan B, Martinson J, Zaunders J, Sasson S, Landay A, et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med 2006;203(7):1693–1700PubMed Seddiki N, Santner-Nanan B, Martinson J, Zaunders J, Sasson S, Landay A, et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med 2006;203(7):1693–1700PubMed
97.
Zurück zum Zitat Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003;299(5609):1057–1061PubMed Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003;299(5609):1057–1061PubMed
98.
Zurück zum Zitat Boulougouris G, McLeod JD, Patel YI, Ellwood CN, Walker LS, Sansom DM. Positive and negative regulation of human T cell activation mediated by the CTLA-4/CD28 ligand CD80. J Immunol 1998;161(8):3919–3924PubMed Boulougouris G, McLeod JD, Patel YI, Ellwood CN, Walker LS, Sansom DM. Positive and negative regulation of human T cell activation mediated by the CTLA-4/CD28 ligand CD80. J Immunol 1998;161(8):3919–3924PubMed
99.
Zurück zum Zitat Agarwal K, Czaja AJ, Jones DE, Donaldson PT. Cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphisms and susceptibility to type 1 autoimmune hepatitis. Hepatology 2000;31(1):49–53PubMed Agarwal K, Czaja AJ, Jones DE, Donaldson PT. Cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphisms and susceptibility to type 1 autoimmune hepatitis. Hepatology 2000;31(1):49–53PubMed
100.
Zurück zum Zitat Longhi MS, Hussain MJ, Bogdanos DP, Quaglia A, Mieli-Vergani G, Ma Y, et al. Cytochrome P450IID6-specific CD8 T cell immune responses mirror disease activity in autoimmune hepatitis type 2. Hepatology 2007;46(2):472–484PubMed Longhi MS, Hussain MJ, Bogdanos DP, Quaglia A, Mieli-Vergani G, Ma Y, et al. Cytochrome P450IID6-specific CD8 T cell immune responses mirror disease activity in autoimmune hepatitis type 2. Hepatology 2007;46(2):472–484PubMed
101.
Zurück zum Zitat Longhi MS, Meda F, Wang P, Samyn M, Mieli-Vergani G, Vergani D, et al. Expansion and de novo generation of potentially therapeutic regulatory T cells in patients with autoimmune hepatitis. Hepatology 2008;47(2):581–591PubMed Longhi MS, Meda F, Wang P, Samyn M, Mieli-Vergani G, Vergani D, et al. Expansion and de novo generation of potentially therapeutic regulatory T cells in patients with autoimmune hepatitis. Hepatology 2008;47(2):581–591PubMed
102.
Zurück zum Zitat Longhi MS, Hussain MJ, Mitry RR, Arora SK, Mieli-Vergani G, Vergani D, et al. Functional study of CD4+CD25+ regulatory T cells in health and autoimmune hepatitis. J Immunol 2006;176(7):4484–4491PubMed Longhi MS, Hussain MJ, Mitry RR, Arora SK, Mieli-Vergani G, Vergani D, et al. Functional study of CD4+CD25+ regulatory T cells in health and autoimmune hepatitis. J Immunol 2006;176(7):4484–4491PubMed
103.
Zurück zum Zitat Mayo MJ, Mosby JM, Jeyarajah R, Combes B, Khilnani S, Al-halimi M, et al. The relationship between hepatic immunoglobulin production and CD154 expression in chronic liver diseases. Liver Int 2006;26(2):187–196PubMed Mayo MJ, Mosby JM, Jeyarajah R, Combes B, Khilnani S, Al-halimi M, et al. The relationship between hepatic immunoglobulin production and CD154 expression in chronic liver diseases. Liver Int 2006;26(2):187–196PubMed
104.
Zurück zum Zitat Grant AJ. Hepatic expression of secondary lymphoid chemokine (CCL21) promotes the development of portal-associated lymphoid tissue in chronic inflammatory liver disease. Am J Pathol 2002;160(4):1445–1455PubMed Grant AJ. Hepatic expression of secondary lymphoid chemokine (CCL21) promotes the development of portal-associated lymphoid tissue in chronic inflammatory liver disease. Am J Pathol 2002;160(4):1445–1455PubMed
105.
Zurück zum Zitat Moritoki Y, Lian ZX, Ohsugi Y, Ueno Y, Gershwin ME. B cells and autoimmune liver diseases. Autoimmun Rev 2006;5(7):449–457PubMed Moritoki Y, Lian ZX, Ohsugi Y, Ueno Y, Gershwin ME. B cells and autoimmune liver diseases. Autoimmun Rev 2006;5(7):449–457PubMed
106.
Zurück zum Zitat Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Autoimmune cholangitis within the spectrum of autoimmune liver disease. Hepatology 2000;31(6):1231–1238PubMed Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Autoimmune cholangitis within the spectrum of autoimmune liver disease. Hepatology 2000;31(6):1231–1238PubMed
107.
Zurück zum Zitat Sanchez-Urdazpal L, Czaja AJ, van Hoek B, Krom RA, Wiesner RH. Prognostic features and role of liver transplantation in severe corticosteroid-treated autoimmune chronic active hepatitis. Hepatology 1992;15(2):215–221 Sanchez-Urdazpal L, Czaja AJ, van Hoek B, Krom RA, Wiesner RH. Prognostic features and role of liver transplantation in severe corticosteroid-treated autoimmune chronic active hepatitis. Hepatology 1992;15(2):215–221
108.
Zurück zum Zitat Montano-Loza AJ, Carpenter HA, Czaja AJ. Consequences of treatment withdrawal in type 1 autoimmune hepatitis. Liver Int 2007;27(4):507–515PubMed Montano-Loza AJ, Carpenter HA, Czaja AJ. Consequences of treatment withdrawal in type 1 autoimmune hepatitis. Liver Int 2007;27(4):507–515PubMed
109.
Zurück zum Zitat Czaja AJ, Carpenter HA. Histological features associated with relapse after corticosteroid withdrawal in type 1 autoimmune hepatitis. Liver Int 2003;23(2):116–123PubMed Czaja AJ, Carpenter HA. Histological features associated with relapse after corticosteroid withdrawal in type 1 autoimmune hepatitis. Liver Int 2003;23(2):116–123PubMed
110.
Zurück zum Zitat Czaja AJ, Carpenter HA. Autoimmune hepatitis. In Portmann BC, Ferrell LD, editors. MacSween’s Pathology of the Liver. Edinburgh: Churchill Livingstone; 2007. 493–517 Czaja AJ, Carpenter HA. Autoimmune hepatitis. In Portmann BC, Ferrell LD, editors. MacSween’s Pathology of the Liver. Edinburgh: Churchill Livingstone; 2007. 493–517
111.
Zurück zum Zitat Czaja AJ, Davis GL, Ludwig J, Baggenstoss AH, Taswell HF. Autoimmune features as determinants of prognosis in steroid-treated chronic active hepatitis of uncertain etiology. Gastroenterology 1983;85(3):713–717PubMed Czaja AJ, Davis GL, Ludwig J, Baggenstoss AH, Taswell HF. Autoimmune features as determinants of prognosis in steroid-treated chronic active hepatitis of uncertain etiology. Gastroenterology 1983;85(3):713–717PubMed
112.
Zurück zum Zitat Czaja AJ, Carpenter HA. Thiopurine methyltransferase deficiency and azathioprine intolerance in autoimmune hepatitis. Dig Dis Sci 2006;51(5):968–975PubMed Czaja AJ, Carpenter HA. Thiopurine methyltransferase deficiency and azathioprine intolerance in autoimmune hepatitis. Dig Dis Sci 2006;51(5):968–975PubMed
113.
Zurück zum Zitat Strassburg CP, Manns MP. Treatment of autoimmune hepatitis. Semin Liver Dis 2009;29(3):273–285PubMed Strassburg CP, Manns MP. Treatment of autoimmune hepatitis. Semin Liver Dis 2009;29(3):273–285PubMed
114.
Zurück zum Zitat Wiegand J, Schuler A, Kanzler S, Lohse A, Beuers U, Kreisel W, et al. Budesonide in previously untreated autoimmune hepatitis. Liver Int 2005;25(5):927–934PubMed Wiegand J, Schuler A, Kanzler S, Lohse A, Beuers U, Kreisel W, et al. Budesonide in previously untreated autoimmune hepatitis. Liver Int 2005;25(5):927–934PubMed
115.
Zurück zum Zitat Danielsson A, Prytz H. Oral budesonide for treatment of autoimmune chronic active hepatitis. Aliment Pharmacol Ther 1994;8(6):585–590PubMedCrossRef Danielsson A, Prytz H. Oral budesonide for treatment of autoimmune chronic active hepatitis. Aliment Pharmacol Ther 1994;8(6):585–590PubMedCrossRef
116.
Zurück zum Zitat Czaja AJ, Lindor KD. Failure of budesonide in a pilot study of treatment-dependent autoimmune hepatitis. Gastroenterology 2000;119(5):1312–1316PubMed Czaja AJ, Lindor KD. Failure of budesonide in a pilot study of treatment-dependent autoimmune hepatitis. Gastroenterology 2000;119(5):1312–1316PubMed
117.
Zurück zum Zitat Rebollo BJ, Cifuentes MC, Pinar MA, Caunedo AA, Salas HE, Jimenez-Saenz M, et al. Deflazacort for long-term maintenance of remission in type I autoimmune hepatitis. Rev Esp Enferm Dig 1999;91(9):630–638 Rebollo BJ, Cifuentes MC, Pinar MA, Caunedo AA, Salas HE, Jimenez-Saenz M, et al. Deflazacort for long-term maintenance of remission in type I autoimmune hepatitis. Rev Esp Enferm Dig 1999;91(9):630–638
118.
Zurück zum Zitat Sherman KE, Narkewicz M, Pinto PC. Cyclosporine in the management of corticosteroid-resistant type I autoimmune chronic active hepatitis. J Hepatol 1994;21(6):1040–1047PubMed Sherman KE, Narkewicz M, Pinto PC. Cyclosporine in the management of corticosteroid-resistant type I autoimmune chronic active hepatitis. J Hepatol 1994;21(6):1040–1047PubMed
119.
Zurück zum Zitat Hyams JS, Ballow M, Leichtner AM. Cyclosporine treatment of autoimmune chronic active hepatitis. Gastroenterology 1987;93(4):890–893PubMed Hyams JS, Ballow M, Leichtner AM. Cyclosporine treatment of autoimmune chronic active hepatitis. Gastroenterology 1987;93(4):890–893PubMed
120.
Zurück zum Zitat van Thiel DH, Wright H, Carroll P, Abu-Elmagd K, Rodriguez-Rilo H, McMichael J, et al. Tacrolimus: a potential new treatment for autoimmune chronic active hepatitis: results of an open-label preliminary trial. Am J Gastroenterol 1995;90(5):771–776PubMed van Thiel DH, Wright H, Carroll P, Abu-Elmagd K, Rodriguez-Rilo H, McMichael J, et al. Tacrolimus: a potential new treatment for autoimmune chronic active hepatitis: results of an open-label preliminary trial. Am J Gastroenterol 1995;90(5):771–776PubMed
121.
Zurück zum Zitat Kanzler S, Gerken G, Dienes HP, Meyer zum Buschenfelde KH, Lohse AW. Cyclophosphamide as alternative immunosuppressive therapy for autoimmune hepatitis—report of three cases. Z Gastroenterol 1997;35(7):571–578PubMed Kanzler S, Gerken G, Dienes HP, Meyer zum Buschenfelde KH, Lohse AW. Cyclophosphamide as alternative immunosuppressive therapy for autoimmune hepatitis—report of three cases. Z Gastroenterol 1997;35(7):571–578PubMed
122.
Zurück zum Zitat Stern RB, Wilkinson SP, Howorth PJ, Williams R. Controlled trial of synthetic d-penicillamine and prednisone in maintenance therapy for active chronic hepatitis. Gut 1977;18(1):19–22PubMed Stern RB, Wilkinson SP, Howorth PJ, Williams R. Controlled trial of synthetic d-penicillamine and prednisone in maintenance therapy for active chronic hepatitis. Gut 1977;18(1):19–22PubMed
123.
Zurück zum Zitat Stern RB, Wilkinson SP, Williams R. Proceedings: controlled trial of d-penicillamine therapy in chronic active hepatitis. Gut 1976;17(5):390PubMed Stern RB, Wilkinson SP, Williams R. Proceedings: controlled trial of d-penicillamine therapy in chronic active hepatitis. Gut 1976;17(5):390PubMed
124.
Zurück zum Zitat Burak KW, Urbanski SJ, Swain MG. Successful treatment of refractory type 1 autoimmune hepatitis with methotrexate. J Hepatol 1998;29(6):990–993PubMed Burak KW, Urbanski SJ, Swain MG. Successful treatment of refractory type 1 autoimmune hepatitis with methotrexate. J Hepatol 1998;29(6):990–993PubMed
125.
Zurück zum Zitat Czaja AJ, Carpenter HA, Lindor KD. Ursodeoxycholic acid as adjunctive therapy for problematic type 1 autoimmune hepatitis: a randomized placebo-controlled treatment trial. Hepatology 1999;30(6):1381–1386PubMed Czaja AJ, Carpenter HA, Lindor KD. Ursodeoxycholic acid as adjunctive therapy for problematic type 1 autoimmune hepatitis: a randomized placebo-controlled treatment trial. Hepatology 1999;30(6):1381–1386PubMed
126.
Zurück zum Zitat Devlin SM, Swain MG, Urbanski SJ, Burak KW. Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory to standard therapy. Can J Gastroenterol 2004;18(5):321–326PubMed Devlin SM, Swain MG, Urbanski SJ, Burak KW. Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory to standard therapy. Can J Gastroenterol 2004;18(5):321–326PubMed
127.
Zurück zum Zitat Richardson PD, James PD, Ryder SD. Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine. J Hepatol 2000;33(3):371–375PubMed Richardson PD, James PD, Ryder SD. Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine. J Hepatol 2000;33(3):371–375PubMed
128.
Zurück zum Zitat Aw MM, Dhawan A, Samyn M, Bargiota A, Mieli-Vergani G. Mycophenolate mofetil as rescue treatment for autoimmune liver disease in children: a 5-year follow-up. J Hepatol 2009;51(1):156–160PubMed Aw MM, Dhawan A, Samyn M, Bargiota A, Mieli-Vergani G. Mycophenolate mofetil as rescue treatment for autoimmune liver disease in children: a 5-year follow-up. J Hepatol 2009;51(1):156–160PubMed
129.
Zurück zum Zitat Hennes EM, Oo YH, Schramm C, Denzer U, Buggisch P, Wiegard C, et al. Mycophenolate mofetil as second line therapy in autoimmune hepatitis? Am J Gastroenterol 2008;103(12):3063–3070PubMed Hennes EM, Oo YH, Schramm C, Denzer U, Buggisch P, Wiegard C, et al. Mycophenolate mofetil as second line therapy in autoimmune hepatitis? Am J Gastroenterol 2008;103(12):3063–3070PubMed
130.
Zurück zum Zitat Santos ES, Arosemena LR, Raez LE, O’Brien C, Regev A. Successful treatment of autoimmune hepatitis and idiopathic thrombocytopenic purpura with the monoclonal antibody, rituximab: case report and review of literature. Liver Int 2006;26(5):625–629PubMed Santos ES, Arosemena LR, Raez LE, O’Brien C, Regev A. Successful treatment of autoimmune hepatitis and idiopathic thrombocytopenic purpura with the monoclonal antibody, rituximab: case report and review of literature. Liver Int 2006;26(5):625–629PubMed
131.
Zurück zum Zitat Zaja F, De VS, Mazzaro C, Sacco S, Damiani D, De MG, et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 2003;101(10):3827–3834PubMed Zaja F, De VS, Mazzaro C, Sacco S, Damiani D, De MG, et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 2003;101(10):3827–3834PubMed
132.
Zurück zum Zitat Saadoun D, Delluc A, Piette JC, Cacoub P. Treatment of hepatitis C-associated mixed cryoglobulinemia vasculitis. Curr Opin Rheumatol 2008;20(1):23–28PubMed Saadoun D, Delluc A, Piette JC, Cacoub P. Treatment of hepatitis C-associated mixed cryoglobulinemia vasculitis. Curr Opin Rheumatol 2008;20(1):23–28PubMed
133.
Zurück zum Zitat Basse G, Ribes D, Kamar N, Mehrenberger M, Esposito L, Guitard J, et al. Rituximab therapy for de novo mixed cryoglobulinemia in renal transplant patients. Transplantation 2005;80(11):1560–1564PubMed Basse G, Ribes D, Kamar N, Mehrenberger M, Esposito L, Guitard J, et al. Rituximab therapy for de novo mixed cryoglobulinemia in renal transplant patients. Transplantation 2005;80(11):1560–1564PubMed
134.
Zurück zum Zitat Basse G, Ribes D, Kamar N, Mehrenberger M, Sallusto F, Esposito L, et al. Rituximab therapy for mixed cryoglobulinemia in seven renal transplant patients. Transplant Proc 2006;38(7):2308–2310PubMed Basse G, Ribes D, Kamar N, Mehrenberger M, Sallusto F, Esposito L, et al. Rituximab therapy for mixed cryoglobulinemia in seven renal transplant patients. Transplant Proc 2006;38(7):2308–2310PubMed
135.
Zurück zum Zitat Hamaki T, Kami M, Kusumi E, Ueyama J, Miyakoshi S, Morinaga S, et al. Prophylaxis of hepatitis B reactivation using lamivudine in a patient receiving rituximab. Am J Hematol 2001;68(4):292–294PubMed Hamaki T, Kami M, Kusumi E, Ueyama J, Miyakoshi S, Morinaga S, et al. Prophylaxis of hepatitis B reactivation using lamivudine in a patient receiving rituximab. Am J Hematol 2001;68(4):292–294PubMed
136.
Zurück zum Zitat Westhoff TH, Jochimsen F, Schmittel A, Stoffler-Meilicke M, Schafer JH, Zidek W, et al. Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. Blood 2003;102(5):1930PubMed Westhoff TH, Jochimsen F, Schmittel A, Stoffler-Meilicke M, Schafer JH, Zidek W, et al. Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. Blood 2003;102(5):1930PubMed
137.
Zurück zum Zitat Weiler-Normann C, Wiegard C, Schramm C, Lohse AW. A case of difficult-to-treat autoimmune hepatitis successfully managed by TNF-alpha blockade. Am J Gastroenterol 2009;104(11):2877–2878PubMed Weiler-Normann C, Wiegard C, Schramm C, Lohse AW. A case of difficult-to-treat autoimmune hepatitis successfully managed by TNF-alpha blockade. Am J Gastroenterol 2009;104(11):2877–2878PubMed
138.
Zurück zum Zitat Germano V, Picchianti DA, Baccano G, Natale E, Onetti MA, Priori R, et al. Autoimmune hepatitis associated with infliximab in a patient with psoriatic arthritis. Ann Rheum Dis 2005;64(10):1519–1520PubMed Germano V, Picchianti DA, Baccano G, Natale E, Onetti MA, Priori R, et al. Autoimmune hepatitis associated with infliximab in a patient with psoriatic arthritis. Ann Rheum Dis 2005;64(10):1519–1520PubMed
139.
Zurück zum Zitat Tobon GJ, Canas C, Jaller JJ, Restrepo JC, Anaya JM. Serious liver disease induced by infliximab. Clin Rheumatol 2007;26(4):578–581PubMed Tobon GJ, Canas C, Jaller JJ, Restrepo JC, Anaya JM. Serious liver disease induced by infliximab. Clin Rheumatol 2007;26(4):578–581PubMed
140.
Zurück zum Zitat Ozorio G, McGarity B, Bak H, Jordan AS, Lau H, Marshall C. Autoimmune hepatitis following infliximab therapy for ankylosing spondylitis. Med J Aust 2007;187(9):524–526PubMed Ozorio G, McGarity B, Bak H, Jordan AS, Lau H, Marshall C. Autoimmune hepatitis following infliximab therapy for ankylosing spondylitis. Med J Aust 2007;187(9):524–526PubMed
141.
Zurück zum Zitat Fairhurst DA, Sheehan-Dare R. Autoimmune hepatitis associated with infliximab in a patient with palmoplantar pustular psoriasis. Clin Exp Dermatol 2009;34(3):421–422PubMed Fairhurst DA, Sheehan-Dare R. Autoimmune hepatitis associated with infliximab in a patient with palmoplantar pustular psoriasis. Clin Exp Dermatol 2009;34(3):421–422PubMed
142.
Zurück zum Zitat Khanna M, Shirodkar MA, Gottlieb AB. Etanercept therapy in patients with autoimmunity and hepatitis C. J Dermatol Treat 2003;14(4):229–232 Khanna M, Shirodkar MA, Gottlieb AB. Etanercept therapy in patients with autoimmunity and hepatitis C. J Dermatol Treat 2003;14(4):229–232
143.
Zurück zum Zitat Becker H, Willeke P, Domschke W, Gaubitz M. Etanercept tolerance in a patient with previous infliximab-induced hepatitis. Clin Rheumatol 2008;27(12):1597–1598PubMed Becker H, Willeke P, Domschke W, Gaubitz M. Etanercept tolerance in a patient with previous infliximab-induced hepatitis. Clin Rheumatol 2008;27(12):1597–1598PubMed
144.
Zurück zum Zitat Goldenberg G, Jorizzo JL. Use of etanercept in treatment of pyoderma gangrenosum in a patient with autoimmune hepatitis. J Dermatol Treat 2005;16(5–6):347–349 Goldenberg G, Jorizzo JL. Use of etanercept in treatment of pyoderma gangrenosum in a patient with autoimmune hepatitis. J Dermatol Treat 2005;16(5–6):347–349
145.
Zurück zum Zitat Morgan AW, Hale G, Rebello PR, Richards SJ, Gooi HC, Waldmann H, et al. A pilot study of combination anti-cytokine and anti-lymphocyte biological therapy in rheumatoid arthritis. QJM 2008;101(4):299–306PubMed Morgan AW, Hale G, Rebello PR, Richards SJ, Gooi HC, Waldmann H, et al. A pilot study of combination anti-cytokine and anti-lymphocyte biological therapy in rheumatoid arthritis. QJM 2008;101(4):299–306PubMed
146.
Zurück zum Zitat Nixon R, Bansback N, Brennan A. The efficacy of inhibiting tumour necrosis factor alpha and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisons. Rheumatology (Oxford) 2007;46(7):1140–1147 Nixon R, Bansback N, Brennan A. The efficacy of inhibiting tumour necrosis factor alpha and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisons. Rheumatology (Oxford) 2007;46(7):1140–1147
147.
Zurück zum Zitat Nishimoto N, Kishimoto T, Yoshizaki K. Anti-interleukin 6 receptor antibody treatment in rheumatic disease. Ann Rheum Dis 2000;59(Suppl 1):i21–i27PubMed Nishimoto N, Kishimoto T, Yoshizaki K. Anti-interleukin 6 receptor antibody treatment in rheumatic disease. Ann Rheum Dis 2000;59(Suppl 1):i21–i27PubMed
148.
Zurück zum Zitat Drewe E, Powell RJ. Clinically useful monoclonal antibodies in treatment. J Clin Pathol 2002;55(2):81–85PubMed Drewe E, Powell RJ. Clinically useful monoclonal antibodies in treatment. J Clin Pathol 2002;55(2):81–85PubMed
149.
Zurück zum Zitat Park JY, Pillinger MH. Interleukin-6 in the pathogenesis of rheumatoid arthritis. Bull NYU Hosp Jt Dis 2007;65(Suppl 1):S4–S10PubMed Park JY, Pillinger MH. Interleukin-6 in the pathogenesis of rheumatoid arthritis. Bull NYU Hosp Jt Dis 2007;65(Suppl 1):S4–S10PubMed
150.
Zurück zum Zitat Guignard S, Dien G, Dougados M. Severe systemic inflammatory response syndrome in a patient with adult onset Still’s disease treated with the anti-IL1 drug anakinra: a case report. Clin Exp Rheumatol 2007;25(5):758–759PubMed Guignard S, Dien G, Dougados M. Severe systemic inflammatory response syndrome in a patient with adult onset Still’s disease treated with the anti-IL1 drug anakinra: a case report. Clin Exp Rheumatol 2007;25(5):758–759PubMed
151.
Zurück zum Zitat van den Berg WB. Arguments for interleukin 1 as a target in chronic arthritis. Ann Rheum Dis 2000;59(Suppl 1):i81–4.PubMed van den Berg WB. Arguments for interleukin 1 as a target in chronic arthritis. Ann Rheum Dis 2000;59(Suppl 1):i81–4.PubMed
152.
Zurück zum Zitat Genovese M, Van Den Bosch F, Roberson S, Bojin S, Biagini I, Ryan P, et al. LY2439821, a humanized anti-IL-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis. Arthritis Rheum (Epub 2010 Jan 21) Genovese M, Van Den Bosch F, Roberson S, Bojin S, Biagini I, Ryan P, et al. LY2439821, a humanized anti-IL-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis. Arthritis Rheum (Epub 2010 Jan 21)
153.
Zurück zum Zitat Durez P, et al. AIN457, an anti-IL-17 antibody, shows good safety and induces clinical responses in patients with active rheumatoid arthritis (RA) despite methotrexate therapy in a randomized, double-blind proof-of-concept trial. Ann Rheum Dis 2010;68(Suppl 3) (abstract LB.002) Durez P, et al. AIN457, an anti-IL-17 antibody, shows good safety and induces clinical responses in patients with active rheumatoid arthritis (RA) despite methotrexate therapy in a randomized, double-blind proof-of-concept trial. Ann Rheum Dis 2010;68(Suppl 3) (abstract LB.002)
154.
Zurück zum Zitat Cinamon G, Matloubian M, Lesneski MJ, Xu Y, Low C, Lu T, et al. Sphingosine 1-phosphate receptor 1 promotes B cell localization in the splenic marginal zone. Nat Immunol 2004;5(7):713–720PubMed Cinamon G, Matloubian M, Lesneski MJ, Xu Y, Low C, Lu T, et al. Sphingosine 1-phosphate receptor 1 promotes B cell localization in the splenic marginal zone. Nat Immunol 2004;5(7):713–720PubMed
155.
Zurück zum Zitat Kahan BD. FTY720: from bench to bedside. Transplant Proc 2004;36(2 Suppl):531S–43SPubMed Kahan BD. FTY720: from bench to bedside. Transplant Proc 2004;36(2 Suppl):531S–43SPubMed
156.
Zurück zum Zitat Rosen H, Sanna G, Alfonso C. Egress: a receptor-regulated step in lymphocyte trafficking. Immunol Rev 2003;195:160–177PubMed Rosen H, Sanna G, Alfonso C. Egress: a receptor-regulated step in lymphocyte trafficking. Immunol Rev 2003;195:160–177PubMed
157.
Zurück zum Zitat Cyster JG. Lymphoid organ development and cell migration. Immunol Rev 2003;195:5–14PubMed Cyster JG. Lymphoid organ development and cell migration. Immunol Rev 2003;195:5–14PubMed
158.
Zurück zum Zitat Rivera J, Proia RL, Olivera A. The alliance of sphingosine-1-phosphate and its receptors in immunity. Nat Rev Immunol 2008;8(10):753–763PubMed Rivera J, Proia RL, Olivera A. The alliance of sphingosine-1-phosphate and its receptors in immunity. Nat Rev Immunol 2008;8(10):753–763PubMed
159.
Zurück zum Zitat Massberg S, von Andrian UH. Fingolimod and sphingosine-1-phosphate—modifiers of lymphocyte migration. N Engl J Med 2006;355(11):1088–1091PubMed Massberg S, von Andrian UH. Fingolimod and sphingosine-1-phosphate—modifiers of lymphocyte migration. N Engl J Med 2006;355(11):1088–1091PubMed
160.
Zurück zum Zitat Bohler T, Budde K, Neumayer HH, Waiser J. Novel mediators of FTY720 in human lymphocytes. Transplantation 2005;79(4):492–495PubMed Bohler T, Budde K, Neumayer HH, Waiser J. Novel mediators of FTY720 in human lymphocytes. Transplantation 2005;79(4):492–495PubMed
161.
Zurück zum Zitat Ledgerwood LG, Lal G, Zhang N, Garin A, Esses SJ, Ginhoux F, et al. The sphingosine 1-phosphate receptor 1 causes tissue retention by inhibiting the entry of peripheral tissue T lymphocytes into afferent lymphatics. Nat Immunol 2008;9(1):42–53PubMed Ledgerwood LG, Lal G, Zhang N, Garin A, Esses SJ, Ginhoux F, et al. The sphingosine 1-phosphate receptor 1 causes tissue retention by inhibiting the entry of peripheral tissue T lymphocytes into afferent lymphatics. Nat Immunol 2008;9(1):42–53PubMed
162.
Zurück zum Zitat Kaneko T, Murakami T, Kawana H, Takahashi M, Yasue T, Kobayashi E. Sphingosine-1-phosphate receptor agonists suppress concanavalin A-induced hepatic injury in mice. Biochem Biophys Res Commun 2006;345(1):85–92PubMed Kaneko T, Murakami T, Kawana H, Takahashi M, Yasue T, Kobayashi E. Sphingosine-1-phosphate receptor agonists suppress concanavalin A-induced hepatic injury in mice. Biochem Biophys Res Commun 2006;345(1):85–92PubMed
163.
Zurück zum Zitat Andersen KG, Butcher T, Betz AG. Specific immunosuppression with inducible Foxp3-transduced polyclonal T cells. PLoS Biol 2008;6(11):e276PubMed Andersen KG, Butcher T, Betz AG. Specific immunosuppression with inducible Foxp3-transduced polyclonal T cells. PLoS Biol 2008;6(11):e276PubMed
164.
Zurück zum Zitat Deknuydt F, Bioley G, Valmori D, Ayyoub M. IL-1beta and IL-2 convert human Treg into T(H)17 cells. Clin Immunol 2009;131(2):298–307PubMed Deknuydt F, Bioley G, Valmori D, Ayyoub M. IL-1beta and IL-2 convert human Treg into T(H)17 cells. Clin Immunol 2009;131(2):298–307PubMed
165.
Zurück zum Zitat Voo KS, Wang YH, Santori FR, Boggiano C, Wang YH, Arima K, et al. Identification of IL-17-producing FOXP3+ regulatory T cells in humans. Proc Natl Acad Sci USA 2009;106(12):4793–4798PubMed Voo KS, Wang YH, Santori FR, Boggiano C, Wang YH, Arima K, et al. Identification of IL-17-producing FOXP3+ regulatory T cells in humans. Proc Natl Acad Sci USA 2009;106(12):4793–4798PubMed
166.
Zurück zum Zitat Koenen HJ, Smeets RL, Vink PM, van Rijseen E, Boots AM, Joosten I. Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells. Blood 2008;112(6):2340–2352 Koenen HJ, Smeets RL, Vink PM, van Rijseen E, Boots AM, Joosten I. Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells. Blood 2008;112(6):2340–2352
167.
Zurück zum Zitat Trowsdale J, Betz AG. Mother’s little helpers: mechanisms of maternal-fetal tolerance. Nat Immunol 2006;7(3):241–246PubMed Trowsdale J, Betz AG. Mother’s little helpers: mechanisms of maternal-fetal tolerance. Nat Immunol 2006;7(3):241–246PubMed
168.
Zurück zum Zitat Aluvihare VR, Kallikourdis M, Betz AG. Tolerance, suppression and the fetal allograft. J Mol Med 2005;83(2):88–96PubMed Aluvihare VR, Kallikourdis M, Betz AG. Tolerance, suppression and the fetal allograft. J Mol Med 2005;83(2):88–96PubMed
169.
Zurück zum Zitat Oo YH, Neuberger J. Use of mycophenolate in the treatment of autoimmune hepatitis. Liver Int 2005;25(4):687–691PubMed Oo YH, Neuberger J. Use of mycophenolate in the treatment of autoimmune hepatitis. Liver Int 2005;25(4):687–691PubMed
170.
Zurück zum Zitat Miyake T, Miyaoka H, Abe M, Furukawa S, Shigematsu S, Furukawa E, et al. Clinical characteristics of autoimmune hepatitis in older aged patients. Hepatol Res 2006;36(2):139–142PubMed Miyake T, Miyaoka H, Abe M, Furukawa S, Shigematsu S, Furukawa E, et al. Clinical characteristics of autoimmune hepatitis in older aged patients. Hepatol Res 2006;36(2):139–142PubMed
171.
Zurück zum Zitat Tripathi D, Neuberger J. Autoimmune hepatitis and liver transplantation: indications, results, and management of recurrent disease. Semin Liver Dis 2009;29(3):286–296PubMed Tripathi D, Neuberger J. Autoimmune hepatitis and liver transplantation: indications, results, and management of recurrent disease. Semin Liver Dis 2009;29(3):286–296PubMed
172.
Zurück zum Zitat Czaja AJ. Special clinical challenges in autoimmune hepatitis: the elderly, males, pregnancy, mild disease, fulminant onset, and nonwhite patients. Semin Liver Dis 2009;29(3):315–330PubMed Czaja AJ. Special clinical challenges in autoimmune hepatitis: the elderly, males, pregnancy, mild disease, fulminant onset, and nonwhite patients. Semin Liver Dis 2009;29(3):315–330PubMed
173.
Zurück zum Zitat Schreuder TC, Hubscher SG, Neuberger J. Autoimmune liver diseases and recurrence after orthotopic liver transplantation: what have we learned so far? Transpl Int 2009;22(2):144–152PubMed Schreuder TC, Hubscher SG, Neuberger J. Autoimmune liver diseases and recurrence after orthotopic liver transplantation: what have we learned so far? Transpl Int 2009;22(2):144–152PubMed
174.
Zurück zum Zitat Vogel A, Heinrich E, Bahr MJ, Rifai K, Flemming P, Melter M, et al. Long-term outcome of liver transplantation for autoimmune hepatitis. Clin Transplant 2004;18(1):62–69PubMed Vogel A, Heinrich E, Bahr MJ, Rifai K, Flemming P, Melter M, et al. Long-term outcome of liver transplantation for autoimmune hepatitis. Clin Transplant 2004;18(1):62–69PubMed
175.
Zurück zum Zitat Duclos-Vallee JC, Sebagh M. Recurrence of autoimmune disease, primary sclerosing cholangitis, primary biliary cirrhosis, and autoimmune hepatitis after liver transplantation. Liver Transpl 2009;15(Suppl 2):S25–S34PubMedCrossRef Duclos-Vallee JC, Sebagh M. Recurrence of autoimmune disease, primary sclerosing cholangitis, primary biliary cirrhosis, and autoimmune hepatitis after liver transplantation. Liver Transpl 2009;15(Suppl 2):S25–S34PubMedCrossRef
176.
Zurück zum Zitat Duclos-Vallee JC, Sebagh M, Rifai K, Johanet C, Ballot E, Guettier C, et al. A 10 year follow up study of patients transplanted for autoimmune hepatitis: histological recurrence precedes clinical and biochemical recurrence. Gut 2003;52(6):893–897PubMed Duclos-Vallee JC, Sebagh M, Rifai K, Johanet C, Ballot E, Guettier C, et al. A 10 year follow up study of patients transplanted for autoimmune hepatitis: histological recurrence precedes clinical and biochemical recurrence. Gut 2003;52(6):893–897PubMed
177.
Zurück zum Zitat Gautam M, Cheruvattath R, Balan V. Recurrence of autoimmune liver disease after liver transplantation: a systematic review. Liver Transpl 2006;12(12):1813–1824PubMed Gautam M, Cheruvattath R, Balan V. Recurrence of autoimmune liver disease after liver transplantation: a systematic review. Liver Transpl 2006;12(12):1813–1824PubMed
178.
Zurück zum Zitat Hubscher SG. Recurrent autoimmune hepatitis after liver transplantation: diagnostic criteria, risk factors, and outcome. Liver Transpl 2001;7(4):285–291PubMed Hubscher SG. Recurrent autoimmune hepatitis after liver transplantation: diagnostic criteria, risk factors, and outcome. Liver Transpl 2001;7(4):285–291PubMed
179.
Zurück zum Zitat Gonzalez-Koch A, Czaja AJ, Carpenter HA, Roberts SK, Charlton MR, Porayko MK, et al. Recurrent autoimmune hepatitis after orthotopic liver transplantation. Liver Transpl 2001;7(4):302–310PubMed Gonzalez-Koch A, Czaja AJ, Carpenter HA, Roberts SK, Charlton MR, Porayko MK, et al. Recurrent autoimmune hepatitis after orthotopic liver transplantation. Liver Transpl 2001;7(4):302–310PubMed
180.
Zurück zum Zitat Salcedo M, Vaquero J, Banares R, Rodriguez-Mahou M, Alvarez E, Vicario JL, et al. Response to steroids in de novo autoimmune hepatitis after liver transplantation. Hepatology 2002;35(2):349–356PubMed Salcedo M, Vaquero J, Banares R, Rodriguez-Mahou M, Alvarez E, Vicario JL, et al. Response to steroids in de novo autoimmune hepatitis after liver transplantation. Hepatology 2002;35(2):349–356PubMed
181.
Zurück zum Zitat Kerkar N, Hadzic N, Davies ET, Portmann B, Donaldson PT, Rela M, et al. De-novo autoimmune hepatitis after liver transplantation. Lancet 1998;351(9100):409–413PubMed Kerkar N, Hadzic N, Davies ET, Portmann B, Donaldson PT, Rela M, et al. De-novo autoimmune hepatitis after liver transplantation. Lancet 1998;351(9100):409–413PubMed
182.
Zurück zum Zitat Heneghan MA, Portmann BC, Norris SM, Williams R, Muiesan P, Rela M, et al. Graft dysfunction mimicking autoimmune hepatitis following liver transplantation in adults. Hepatology 2001;34(3):464–470PubMed Heneghan MA, Portmann BC, Norris SM, Williams R, Muiesan P, Rela M, et al. Graft dysfunction mimicking autoimmune hepatitis following liver transplantation in adults. Hepatology 2001;34(3):464–470PubMed
183.
Zurück zum Zitat D’Antiga L, Dhawan A, Portmann B, Francavilla R, Rela M, Heaton N, et al. Late cellular rejection in paediatric liver transplantation: aetiology and outcome. Transplantation 2002;73(1):80–84PubMed D’Antiga L, Dhawan A, Portmann B, Francavilla R, Rela M, Heaton N, et al. Late cellular rejection in paediatric liver transplantation: aetiology and outcome. Transplantation 2002;73(1):80–84PubMed
184.
Zurück zum Zitat Miyagawa-Hayashino A, Haga H, Egawa H, Hayashino Y, Sakurai T, Minamiguchi S, et al. Outcome and risk factors of de novo autoimmune hepatitis in living-donor liver transplantation. Transplantation 2004;78(1):128–135PubMed Miyagawa-Hayashino A, Haga H, Egawa H, Hayashino Y, Sakurai T, Minamiguchi S, et al. Outcome and risk factors of de novo autoimmune hepatitis in living-donor liver transplantation. Transplantation 2004;78(1):128–135PubMed
185.
Zurück zum Zitat Mieli-Vergani G, Vergani D. De novo autoimmune hepatitis after liver transplantation. J Hepatol 2004;40(1):3–7PubMed Mieli-Vergani G, Vergani D. De novo autoimmune hepatitis after liver transplantation. J Hepatol 2004;40(1):3–7PubMed
186.
Zurück zum Zitat Venick RS, McDiarmid SV, Farmer DG, Gornbein J, Martin MG, Vargas JH, et al. Rejection and steroid dependence: unique risk factors in the development of pediatric posttransplant de novo autoimmune hepatitis. Am J Transplant 2007;7(4):955–963PubMed Venick RS, McDiarmid SV, Farmer DG, Gornbein J, Martin MG, Vargas JH, et al. Rejection and steroid dependence: unique risk factors in the development of pediatric posttransplant de novo autoimmune hepatitis. Am J Transplant 2007;7(4):955–963PubMed
187.
Zurück zum Zitat Avitzur Y, Ngan BY, Lao M, Fecteau A, Ng VL. Prospective evaluation of the prevalence and clinical significance of positive autoantibodies after pediatric liver transplantation. J Pediatr Gastroenterol Nutr 2007;45(2):222–227PubMed Avitzur Y, Ngan BY, Lao M, Fecteau A, Ng VL. Prospective evaluation of the prevalence and clinical significance of positive autoantibodies after pediatric liver transplantation. J Pediatr Gastroenterol Nutr 2007;45(2):222–227PubMed
188.
Zurück zum Zitat Duclos-Vallee JC, Johanet C, Bach JF, Yamamoto AM. Autoantibodies associated with acute rejection after liver transplantation for type-2 autoimmune hepatitis. J Hepatol 2000;33(1):163–166PubMed Duclos-Vallee JC, Johanet C, Bach JF, Yamamoto AM. Autoantibodies associated with acute rejection after liver transplantation for type-2 autoimmune hepatitis. J Hepatol 2000;33(1):163–166PubMed
189.
Zurück zum Zitat Lohse AW, Obermayer-Straub P, Gerken G, Brunner S, Altes U, Dienes HP, et al. Development of cytochrome P450 2D6-specific LKM-autoantibodies following liver transplantation for Wilson’s disease—possible association with a steroid-resistant transplant rejection episode. J Hepatol 1999;31(1):149–155PubMed Lohse AW, Obermayer-Straub P, Gerken G, Brunner S, Altes U, Dienes HP, et al. Development of cytochrome P450 2D6-specific LKM-autoantibodies following liver transplantation for Wilson’s disease—possible association with a steroid-resistant transplant rejection episode. J Hepatol 1999;31(1):149–155PubMed
190.
Zurück zum Zitat Riva S, Sonzogni A, Bravi M, Bertani A, Alessio MG, Candusso M, et al. Late graft dysfunction and autoantibodies after liver transplantation in children: preliminary results of an Italian experience. Liver Transpl 2006;12(4):573–577PubMed Riva S, Sonzogni A, Bravi M, Bertani A, Alessio MG, Candusso M, et al. Late graft dysfunction and autoantibodies after liver transplantation in children: preliminary results of an Italian experience. Liver Transpl 2006;12(4):573–577PubMed
191.
Zurück zum Zitat Fiel MI, Agarwal K, Stanca C, Elhajj N, Kontorinis N, Thung SN, et al. Posttransplant plasma cell hepatitis (de novo autoimmune hepatitis) is a variant of rejection and may lead to a negative outcome in patients with hepatitis C virus. Liver Transpl 2008;14(6):861–871PubMed Fiel MI, Agarwal K, Stanca C, Elhajj N, Kontorinis N, Thung SN, et al. Posttransplant plasma cell hepatitis (de novo autoimmune hepatitis) is a variant of rejection and may lead to a negative outcome in patients with hepatitis C virus. Liver Transpl 2008;14(6):861–871PubMed
192.
Zurück zum Zitat Cholongitas E, Samonakis D, Patch D, Senzolo M, Burroughs AK, Quaglia A, et al. Induction of autoimmune hepatitis by pegylated interferon in a liver transplant patient with recurrent hepatitis C virus. Transplantation 2006;81(3):488–490PubMed Cholongitas E, Samonakis D, Patch D, Senzolo M, Burroughs AK, Quaglia A, et al. Induction of autoimmune hepatitis by pegylated interferon in a liver transplant patient with recurrent hepatitis C virus. Transplantation 2006;81(3):488–490PubMed
193.
Zurück zum Zitat Kontorinis N, Agarwal K, Elhajj N, Fiel MI, Schiano TD. Pegylated interferon-induced immune-mediated hepatitis post-liver transplantation. Liver Transpl 2006;12(5):827–830PubMed Kontorinis N, Agarwal K, Elhajj N, Fiel MI, Schiano TD. Pegylated interferon-induced immune-mediated hepatitis post-liver transplantation. Liver Transpl 2006;12(5):827–830PubMed
194.
Zurück zum Zitat Berardi S, Lodato F, Gramenzi A, D’Errico A, Lenzi M, Bontadini A, et al. High incidence of allograft dysfunction in liver transplanted patients treated with pegylated-interferon alpha-2b and ribavirin for hepatitis C recurrence: possible de novo autoimmune hepatitis? Gut 2007;56(2):237–242PubMed Berardi S, Lodato F, Gramenzi A, D’Errico A, Lenzi M, Bontadini A, et al. High incidence of allograft dysfunction in liver transplanted patients treated with pegylated-interferon alpha-2b and ribavirin for hepatitis C recurrence: possible de novo autoimmune hepatitis? Gut 2007;56(2):237–242PubMed
195.
Zurück zum Zitat Aguilera I, Sousa JM, Gavilan F, Bernardos A, Wichmann I, Nunez-Roldan A. Glutathione S-transferase T1 mismatch constitutes a risk factor for de novo immune hepatitis after liver transplantation. Liver Transpl 2004;10(9):1166–1172PubMed Aguilera I, Sousa JM, Gavilan F, Bernardos A, Wichmann I, Nunez-Roldan A. Glutathione S-transferase T1 mismatch constitutes a risk factor for de novo immune hepatitis after liver transplantation. Liver Transpl 2004;10(9):1166–1172PubMed
196.
Zurück zum Zitat Aguilera I, Sousa JM, Gavilan F, Bernardos A, Wichmann I, Nunez-Roldan A. Glutathione S-transferase T1 genetic mismatch is a risk factor for de novo immune hepatitis in liver transplantation. Transplant Proc 2005;37(9):3968–3969PubMed Aguilera I, Sousa JM, Gavilan F, Bernardos A, Wichmann I, Nunez-Roldan A. Glutathione S-transferase T1 genetic mismatch is a risk factor for de novo immune hepatitis in liver transplantation. Transplant Proc 2005;37(9):3968–3969PubMed
197.
Zurück zum Zitat Rodriguez-Mahou M, Salcedo M, Fernandez-Cruz E, Tiscar JL, Banares R, Clemente G, et al. Antibodies against glutathione S-transferase T1 (GSTT1) in patients with GSTT1 null genotype as prognostic marker: long-term follow-up after liver transplantation. Transplantation 2007;83(8):1126–1129PubMed Rodriguez-Mahou M, Salcedo M, Fernandez-Cruz E, Tiscar JL, Banares R, Clemente G, et al. Antibodies against glutathione S-transferase T1 (GSTT1) in patients with GSTT1 null genotype as prognostic marker: long-term follow-up after liver transplantation. Transplantation 2007;83(8):1126–1129PubMed
198.
Zurück zum Zitat Salcedo M, Rodriguez-Mahou M, Rodriguez-Sainz C, Rincon D, Alvarez E, Vicario JL, et al. Risk factors for developing de novo autoimmune hepatitis associated with anti-glutathione-S-transferase T1 antibodies after liver transplantation. Liver Transpl 2009;15(5):530–539PubMed Salcedo M, Rodriguez-Mahou M, Rodriguez-Sainz C, Rincon D, Alvarez E, Vicario JL, et al. Risk factors for developing de novo autoimmune hepatitis associated with anti-glutathione-S-transferase T1 antibodies after liver transplantation. Liver Transpl 2009;15(5):530–539PubMed
199.
Zurück zum Zitat Yoshizawa K, Shirakawa H, Ichijo T, Umemura T, Tanaka E, Kiyosawa K, et al. De novo autoimmune hepatitis following living-donor liver transplantation for primary biliary cirrhosis. Clin Transplant 2008;22(3):385–390PubMedCrossRef Yoshizawa K, Shirakawa H, Ichijo T, Umemura T, Tanaka E, Kiyosawa K, et al. De novo autoimmune hepatitis following living-donor liver transplantation for primary biliary cirrhosis. Clin Transplant 2008;22(3):385–390PubMedCrossRef
200.
Zurück zum Zitat Grammatikopoulos. AASLD; 2010 (abstract 706) Grammatikopoulos. AASLD; 2010 (abstract 706)
201.
Zurück zum Zitat Richter A, Grabhorn E, Helmke K, Manns MP, Ganschow R, Burdelski M. Clinical relevance of autoantibodies after pediatric liver transplantation. Clin Transplant 2007;21(3):427–432PubMed Richter A, Grabhorn E, Helmke K, Manns MP, Ganschow R, Burdelski M. Clinical relevance of autoantibodies after pediatric liver transplantation. Clin Transplant 2007;21(3):427–432PubMed
202.
Zurück zum Zitat Shaikh OS, Demetris AJ. Idiopathic posttransplantation hepatitis? Liver Transpl 2007;13(7):943–946PubMed Shaikh OS, Demetris AJ. Idiopathic posttransplantation hepatitis? Liver Transpl 2007;13(7):943–946PubMed
203.
Zurück zum Zitat Herzog D, Soglio DB, Fournet JC, Martin S, Marleau D, Alvarez F. Interface hepatitis is associated with a high incidence of late graft fibrosis in a group of tightly monitored pediatric orthotopic liver transplantation patients. Liver Transpl 2008;14(7):946–955PubMed Herzog D, Soglio DB, Fournet JC, Martin S, Marleau D, Alvarez F. Interface hepatitis is associated with a high incidence of late graft fibrosis in a group of tightly monitored pediatric orthotopic liver transplantation patients. Liver Transpl 2008;14(7):946–955PubMed
204.
Zurück zum Zitat Evans HM. Progressive histological damage in liver allografts following pediatric liver transplantation. Hepatology 2006;43(5):1109–1117PubMed Evans HM. Progressive histological damage in liver allografts following pediatric liver transplantation. Hepatology 2006;43(5):1109–1117PubMed
205.
Zurück zum Zitat Syn WK. Natural history of unexplained chronic hepatitis after liver transplantation. Liver Transpl 2007;13(7):984–989PubMed Syn WK. Natural history of unexplained chronic hepatitis after liver transplantation. Liver Transpl 2007;13(7):984–989PubMed
206.
Zurück zum Zitat Hubscher S. What does the long-term liver allograft look like for the pediatric recipient? Liver Transpl 2009;15(Suppl 2):S19–S24PubMedCrossRef Hubscher S. What does the long-term liver allograft look like for the pediatric recipient? Liver Transpl 2009;15(Suppl 2):S19–S24PubMedCrossRef
Metadaten
Titel
Autoimmune hepatitis: new paradigms in the pathogenesis, diagnosis, and management
verfasst von
Ye H. Oo
Stefan G. Hubscher
David H. Adams
Publikationsdatum
01.06.2010
Verlag
Springer-Verlag
Erschienen in
Hepatology International / Ausgabe 2/2010
Print ISSN: 1936-0533
Elektronische ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-010-9183-5

Weitere Artikel der Ausgabe 2/2010

Hepatology International 2/2010 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.